Michael Siluk | Education pictures | Universal Images Group | Getty pictures
Company: Medtronic PLC (MDT)
Business: Medtronic PLC is a company based in Ireland that offers solutions for health technology. The company's category includes advanced surgical technology. Heart rhythm; Cardiovascular system; Digestion & gastrointestinal; Ears, nose & neck; General operation; Gynecological; Neurological; Oral & Maxillofacial; Patient monitoring; Kidney care; Respiration; Spine & orthopedic; Surgical navigation & imaging; Urological; Product manuals; Product order & inquiries; and product performance and advice. The products include cardiac implantable stabilization of Electronic Device (CED), Aortenstent Transplant Products, Carelink Personal Therapy Management software, Carelink Pro therapy management software. The services and solutions include resources for outpatient surgery, support for care management, support for digital connectivity technology (IT), device services and support, innovation Lab, Medtronic Healthcare Consulting and Office-based sinus surgery.
Market value: $ 118.78 billion ($ 92.71 per share)
Stock Diagram -iconstock -Igram -Symbol
Medtronic shares in 2025
Activist: Elliott Investment Management
Property: n/a
Average costs: n/a
Activist comment: Elliott is a very successful and clever activist investor. The company of the company includes analysts of leading technical equity companies, engineers, company partners -former technology CEO and COOS. When evaluating an investment, the company also hires special and general management consultants, expert cost analysts and industry specialists. Elliott often observes companies many years before investing and has an extensive stable impressive board candidates. The company has historically focused on strategic activism in the technology sector and was very successful with this strategy. However, their activism group has grown in recent years, and Elliott has carried out much more governance -oriented activism and creates value from a much larger width of companies.
What happens
On August 19, Medtronic PLC announced the appointment of John Groetelaars (former interim CEO of Dentspy Sirona and former president and CEO of Hillrom) and Bill Jellison (former Vice President CFO of Stryker) to the board with Elliott. In addition, the board announced the formation of the growth committee and the company committee. Jellison will serve in both, while Groetelaars will join the growth committee.
Behind the scenes
Medtronic is the world's largest Medtech company after incomePresent With a story of Medtech innovation and market leadership from the 1940s. While his cardiology segment continues to be his legacy nucleus (37% of sales), Medtronic is today a diversified operator with his other segments, including neurosciences (29%), medical surgery (25% and largely from the acquisition of covidia that were closed in 2015) and other (9%, primarily diabetes treatment). Despite this positioning as a one-stop shop for medical devices, Medtronic's share price stagnated and has only estimated 15% in the past ten years and 8% in the past five years.
This equity performance underlines the frustration of the long -term investor in Medtronic's growth profile. Due to the company's attractive end markets and scale, investors have been waiting for a growth engineer for a long time, but Medtronic has achieved growing growth in sales with medium Sinedle digits in the past 10 years. Many have speculated that Medtronic's growth is disappointed due to its diversification strategy. While Medtech colleagues such as Boston Scientific and Intuitive surgical pursue depth rather than diversification, carry out tuck-in fusions and acquisitions and build up the scale in focused markets, Medtronic has been on the side line since the acquisition of Covidia and left them with a larger sales basis as peers.
For the first time in many years, however, management sends a message to the market that it not only recognizes this problem, but also does something about it. This message is made in the form of a creation of a growth committee and the newly appointed, newly appointed director Bill Jellison (former Vice President and CFO from Stryker). Remarkably, these measures were taken after Elliott's commitment. The growth committee is based on portfolio management, including the search for Tuck-in-M & A opportunities to supplement organic growth, research and develop research and development and review its existing corporate portfolio for inefficiencies for persecution of future financial sales. For this purpose, Jellison will be a value creation director. In addition, Elliott has shown that it can be a valuable active shareholder for an Elliott principle even without a board seat, especially when evaluating and executing M&A opportunities.
Medtech has also found Margin's challenges in recent years, and management also deals with the formation of a company committee. This committee focuses on the creation of space in the P&L and gross margin. As with most Medtech companies, Medtronic has been subject to great negative pressure since the Covid 19 pandemic. While the same age generally experienced 100 to 200 basis of the outskirts, the gross margins from Medtronic (now around 65%) have interrupted about 500 BISTPT. This is another area in which Elliott supported portfolio companies as an active shareholder.
While these two committees are new, you can start with a little swing. Medtronic announced in May that within the next 15 months it will be rounded off its diabetes business, which should help the company concentrate on its core business. There are also two product developments that could make sense to grow long -term growth: (i) pulseselect, an impulse field dilappling system for the treatment of atrial fibrillation, which was launched in the USA in 2024 and has grown quickly in the course of this year. And (II) Symplicity Spyrral, a kidney product used for the treatment of high blood pressure, recently received a favorable reimbursement decision from the Centers for Medicare & Medicaid services, which was completed in October, which should significantly increase access and introduction of the product. While these product developments are certainly reasons for optimistic, for shareholders such as Elliott is a professional and sophisticated process, and with these operational and governance changes, shareholders should be confident that the company finally has a process that can achieve long-term growth. In order to paraphrase from the book “Built to Constant: Successful Habbits of Visionaire”, it is the difference between Time Teller and Clock Builder. The most successful and constant companies were Clock builders.
Elliott is one of today's most productive activists and has already successfully completed the activist phase of this engagement. Now is the time for phase two: a turn of the business. Elliott has contributed to adding two directors to the board that are special for this situation. Both Jellison and Groetelaars have extensive MedTech experience, and Jellison has active Masimo for the political capital and Anika Therapeutics for Caligan partners in the board of two other MedTech companies. What makes this commitment unique is that Elliott has not concluded a formal agreement with Medtronically and signaled that management did not consider it necessary and that Elliott supports his efforts. While the stage is currently set for a long -term, mutual relationship between the two parties, Elliott has been able to have a unique flexibility if things are not as planned, but we do not expect that they have to rely on this emergency care.
Ken Squire is the founder and president of 13D monitor, an institutional research service for shareholders, and the founder and portfolio manager of the 13D Activist Fund, an investment fund that invests in an activist 13D investment.